Clinical Trials Browser

NIH × Endometrial Adenocarcinoma × Clear all

NCT00977574 2025-10-31

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT01307631 2022-02-11

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Phase 2 Completed

37 enrolled 9 charts

Endometrial Adenocarcinoma

NCT01935973 2020-10-14

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 1 Completed

Endometrial Adenocarcinoma

NCT00478426 2020-02-17

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Phase 2 Completed

34 enrolled 10 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT01132820 2019-08-08

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

53 enrolled 11 charts

Endometrial Adenocarcinoma

NCT00006089 2019-07-31

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Completed

Endometrial Adenocarcinoma